We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Advanced Micro Devices (AMD - Free Report) ) has strengthened its position in the semiconductor market on the back of its strong product portfolio. AMD is benefiting from broadening AI infrastructure demand as EPYC server CPUs and Instinct accelerators gain traction across cloud and enterprise customers. Helios is beginning its production ramp, while multigigawatt commitments from leading model developers improve visibility into AI deployments. Venice strengthens the server roadmap, and management expects server growth to remain elevated into 2027. Client share gains and an Embedded recovery add diversification. For the current quarter, Advanced Micro is expected to post earnings indicating a change of +90.9% from the year-ago quarter. The Zacks Consensus Estimate has changed +14.1% over the last 30 days. For the current fiscal year, the consensus earnings estimate points to a change of +92.8% from the prior year. Over the last 30 days, this estimate has changed +6.8%. For the next fiscal year, the consensus earnings estimate of $17.28 indicates a change of +115% from what Advanced Micro is expected to report a year ago.
Moderna, Inc. (MRNA - Free Report) ) is a commercial-stage pharmaceutical company primarily focused on discovering and developing messenger RNA (mRNA)-based therapies.European approval of the first influenza/COVID-19 combination vaccine and FDA approval of mFlusiva strengthen Moderna’s efforts to build a broader respiratory franchise beyond COVID-19. The Merck-partnered personalized cancer therapy has emerged as a potential growth driver after positive phase III melanoma data, with a possible 2027 launch. Pandemic-era COVID sales left Moderna with substantial cash to fund pipeline development across several therapeutic areas. Moderna’s collaboration model continues to support pipeline development by bringing in external funding, expertise and cost sharing. Moderna, Inc.raised its 2026 revenue outlook following stronger-than-expected third-quarter sales, supported by increased COVID vaccine demand, international partnerships and improved commercial execution. Third-quarter revenues increased 29% year over year exceeding the Zacks Consensus Estimate by 47.70%.
View the Zacks #1 Rank List
Top Stock Picks for Week of November 9, 2026
Advanced Micro Devices (AMD - Free Report) ) has strengthened its position in the semiconductor market on the back of its strong product portfolio. AMD is benefiting from broadening AI infrastructure demand as EPYC server CPUs and Instinct accelerators gain traction across cloud and enterprise customers. Helios is beginning its production ramp, while multigigawatt commitments from leading model developers improve visibility into AI deployments. Venice strengthens the server roadmap, and management expects server growth to remain elevated into 2027. Client share gains and an Embedded recovery add diversification. For the current quarter, Advanced Micro is expected to post earnings indicating a change of +90.9% from the year-ago quarter. The Zacks Consensus Estimate has changed +14.1% over the last 30 days. For the current fiscal year, the consensus earnings estimate points to a change of +92.8% from the prior year. Over the last 30 days, this estimate has changed +6.8%. For the next fiscal year, the consensus earnings estimate of $17.28 indicates a change of +115% from what Advanced Micro is expected to report a year ago.
Moderna, Inc. (MRNA - Free Report) ) is a commercial-stage pharmaceutical company primarily focused on discovering and developing messenger RNA (mRNA)-based therapies.European approval of the first influenza/COVID-19 combination vaccine and FDA approval of mFlusiva strengthen Moderna’s efforts to build a broader respiratory franchise beyond COVID-19. The Merck-partnered personalized cancer therapy has emerged as a potential growth driver after positive phase III melanoma data, with a possible 2027 launch. Pandemic-era COVID sales left Moderna with substantial cash to fund pipeline development across several therapeutic areas. Moderna’s collaboration model continues to support pipeline development by bringing in external funding, expertise and cost sharing. Moderna, Inc.raised its 2026 revenue outlook following stronger-than-expected third-quarter sales, supported by increased COVID vaccine demand, international partnerships and improved commercial execution. Third-quarter revenues increased 29% year over year exceeding the Zacks Consensus Estimate by 47.70%.